Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 2CNS 2Other solid neoplasm 1Head & Neck 1Gynecologic 1Genitourinary 1Breast 1

Conditions

Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Head and Neck Neoplasms 1Colorectal Neoplasms 1

Interventions

Paclitaxel 100Trastuzumab 81pembrolizumab 78Fulvestrant 68Cyclophosphamide 66Carboplatin 49Capecitabine 47Docetaxel 45palbociclib 41Lapatinib 40Letrozole 37Doxorubicin 29olaparib 28Taxes 28Nivolumab 25Magnetic Resonance Spectroscopy 25Gemcitabine 25130-nm albumin-bound paclitaxel 25Everolimus 23Biopsy 23ribociclib 22abemaciclib 21Specimen Handling 21Albumin-Bound Paclitaxel 21Cisplatin 20Radiotherapy 19Bevacizumab 19Ado-Trastuzumab Emtansine 19pertuzumab 17Alpelisib 17

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Ferrosoferric Oxide × Breast × Clear all
NCT01770353 2019-11-27

MM-398 (Nanoliposomal Irinotecan, Nal-IRI) to Determine Tumor Drug Levels and to Evaluate the Feasibility of Ferumoxytol Magnetic Resonance Imaging to Measure Tumor Associated Macrophages and to Predict Patient Response to Treatment

Ipsen

Phase 1 Completed
45 enrolled 33 charts
BreastGastrointestinalGynecologicHead & Neck

Head and Neck Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡